Epidemiology, Drug Resistance, and Risk Factors for Mortality Among Hematopoietic Stem Cell Transplantation Recipients with Hospital-Acquired Klebsiella pneumoniae Infections: A Single-Center Retrospective Study from China

References

• Narinx J, Servais S, Baron F, Beguin Y, Willems E. Allogeneic hematopoietic stem cell transplantation: general principles and recent progress. Rev Med Liege. 2021;76(5–6):464–469.
   Google Scholar
• Sahin U, Toprak SK, Atilla PA, et al. An overview of infectious complications after allogeneic hematopoietic stem cell transplantation. J Infect Chemother. 2016;22(8):505–514. doi:10.1016/j.jiac.2016.05.006
   PubMed Web of Science ®Google Scholar
• Omrani AS, Almaghrabi RS. Complications of hematopoietic stem cell transplantation: bacterial infections. Hematol Oncol Stem Cell Ther. 2017;10(4):228–232. doi:10.1016/j.hemonc.2017.05.018
   Google Scholar
• Effah CY, Sun T, Liu S, et al. Klebsiella pneumoniae: an increasing threat to public health. Ann Clin Microbiol Antimicrob. 2020;19(1):1–9. doi:10.1186/s12941-019-0343-8
   PubMed Web of Science ®Google Scholar
• Micozzi A, Gentile G, Minotti C, et al. Carbapenem-resistant Klebsiella pneumoniae in high-risk haematological patients: factors favouring spread, risk factors and outcome of carbapenem-resistant Klebsiella pneumoniae bacteremias. BMC Infect Dis. 2017;17(1):1–12. doi:10.1186/s12879-017-2297-9
   PubMed Web of Science ®Google Scholar
• Kalpoe JS, Sonnenberg E, Factor SH, et al. Mortality associated with carbapenem-resistant Klebsiella pneumoniae infections in liver transplant recipients. Liver Transpl. 2012;18(4):468–474. doi:10.1002/lt.23374
   PubMed Web of Science ®Google Scholar
• Zheng B, Dai Y, Liu Y, et al. Molecular epidemiology and risk factors of carbapenem-resistant Klebsiella pneumoniae infections in Eastern China. Front Microbiol. 2017;8:1061. doi:10.3389/fmicb.2017.01061
   PubMed Web of Science ®Google Scholar
• Hu Y, Liu C, Shen Z, et al. Prevalence, risk factors and molecular epidemiology of carbapenem-resistant Klebsiella pneumoniae in patients from Zhejiang, China, 2008–2018. Emerg Microbes Infect. 2020;9(1):1771–1779. doi:10.1080/22221751.2020.1799721
   PubMed Web of Science ®Google Scholar
• Asai S, Ohshima T, Iwashita H, et al. Carbapenem-resistant Klebsiella pneumoniae in a febrile neutropenia patient with acute myelogenous leukemia after hematopoietic stem cell transplantation. Infect Dis Clin Pract. 2018;26(5):e38–e39. doi:10.1097/IPC.0000000000000633
   Web of Science ®Google Scholar
• Hematology Oncology Committee, Chinese Anti-Cancer Association, Leukemia & Lymphoma Group, Chinese Society of Hematology. Chinese guidelines for diagnosis and treatment of adult acute lymphoblastic leukemia (2021). Chin J Hematol. 2021;42(9):705–716.
   Google Scholar
• Leukemia & Lymphoma Group, Chinese Society of Hematology, Chinese Medical Association. Chinese guidelines for the diagnosis and treatment of adult acute myeloid leukemia (not APL) (2021). Chin J Hematol. 2021;42(8):617–623.
   Google Scholar
• Chinese Society of Hematology, Chinese Medical Association. Chinese guidelines for diagnosis and treatment of myelodysplastic syndromes (2019). Chin J Hematol. 2019;40(2):89–97.
   Google Scholar
• Red Blood Cell Disease (Anemia) Group, Chinese Society of Hematology, Chinese Medical Association. Chinese expert consensus on the diagnosis and treatment of aplastic anemia (2017). Chin J Hematol. 2017;38(1):1–5.
   Google Scholar
• Hoppe RT, Advani RH, Ai WZ, et al. Hodgkin lymphoma, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(6):755–781. doi:10.6004/jnccn.2020.0026
   PubMed Web of Science ®Google Scholar
• Cao Z, Yue C, Kong Q, et al. Risk factors for a hospital-acquired carbapenem-resistant Klebsiella pneumoniae bloodstream infection: a five-year retrospective study. Infect Drug Resist. 2022;15:641–654. doi:10.2147/IDR.S342103
   Web of Science ®Google Scholar
• Shankar-Hari M, Phillips GS, Levy ML, et al. Developing a new definition and assessing new clinical criteria for septic shock: for the third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):775–787. doi:10.1001/jama.2016.0289
   PubMed Web of Science ®Google Scholar
• Stem Cell Application Group, Chinese Society of Hematology, Chinese Medical Association. Chinese consensus of allogeneic hematopoietic stem cell transplantation for hematological disease (III)-acute graft-versus-host disease (2020). Zhonghua Xueyexue Zazhi. 2020;41(7):529–536. doi:10.3760/cma.j.issn.0253-2727.2020.07.001
   Google Scholar
• Wan Q, Liu H, Ye S, et al. Confirmed transmission of bacterial or fungal infection to kidney transplant recipients from donated after cardiac death (DCD) donors in China: a single-center analysis. Med Sci Monit. 2017;23:3770–3779. doi:10.12659/MSM.901884
   Web of Science ®Google Scholar
• Di W, Chen CM, Liu TH, et al. Risk factors for acquisition of carbapenem-resistant Klebsiella pneumoniae and mortality among abdominal solid organ transplant recipients with K. pneumoniae infections. Med Sci Monit. 2020;26:e922996. doi:10.12659/MSM.922996
   Web of Science ®Google Scholar
• Diekema DJ, Hsueh PR, Mendes RE, et al. The microbiology of bloodstream infection: 20-year trends from the SENTRY antimicrobial surveillance program. Antimicrob Agents Chemother. 2019;63(7):e00355–19. doi:10.1128/AAC.00355-19
   PubMed Web of Science ®Google Scholar
• Tian L, Sun Z, Zhang Z. Antimicrobial resistance of pathogens causing nosocomial bloodstream infection in Hubei Province, China, from 2014 to 2016: a multicenter retrospective study. BMC Public Health. 2018;18(1):1121. doi:10.1186/s12889-018-6013-5
   PubMed Web of Science ®Google Scholar
• Mohd Asri NA, Ahmad S, Mohamud R, et al. Global prevalence of nosocomial multidrug-resistant Klebsiella pneumoniae: a systematic review and meta-analysis. Antibiotics. 2021;10(12):1508. doi:10.3390/antibiotics10121508
   Web of Science ®Google Scholar
• Iosifidis E, Chorafa E, Agakidou E, et al. Use of ceftazidime-avibactam for the treatment of extensively drug-resistant or pan drug-resistant Klebsiella pneumoniae in neonates and children< 5 years of age. Pediatr Infect Dis J. 2019;38(8):812–815. doi:10.1097/INF.0000000000002344
   Web of Science ®Google Scholar
• Higashino HR, Marchi AP, Martins RCR, et al. Carbapenem-resistant Klebsiella pneumoniae colonization and infection is associated with lower overall survival in a cohort of haematopoietic stem-cell transplantation patients: mechanism of resistance and virulence by whole-genome sequencing. J Med Microbiol. 2021;70(10):1422. doi:10.1099/jmm.0.001422
   Web of Science ®Google Scholar
• Gavriilaki E, Sakellari I, Chatzikonstantinou T, et al. Risk factors and outcomes of Klebsiella pneumoniae infection before and after allogeneic hematopoietic cell transplantation. Front Med. 2020;7:608165. doi:10.3389/fmed.2020.608165
   Web of Science ®Google Scholar
• Forcina A, Baldan R, Marasco V, et al. Control of infectious mortality due to Carbapenemase-producing Klebsiella pneumoniae in hematopoietic stem cell transplantation. Bone Marrow Transplant. 2017;52(1):114–119. doi:10.1038/bmt.2016.234
   PubMed Web of Science ®Google Scholar
• Han QZ, Chen Y, Yang H, et al. Incidence of blood stream infections of 1265 patients with hematopoietic stem cell transplantation and analysis of pathogenic bacteria. Zhonghua Xue Ye Xue Za Zhi. 2017;38(11):930–933. doi:10.3760/cma.j.issn.0253-2727.2017.11.005
   Google Scholar
• Lou W, Venkataraman S, Zhong G, et al. Antimicrobial polymers as therapeutics for treatment of multidrug-resistant Klebsiella pneumoniae lung infection. Acta Biomater. 2018;78:78–88. doi:10.1016/j.actbio.2018.07.038
   PubMed Web of Science ®Google Scholar
• Hu F, Zhu D, Wang F, et al. Current status and trends of antibacterial resistance in China. Clin Infect Dis. 2018;67(suppl_2):S128–134. doi:10.1093/cid/ciy657
   PubMed Web of Science ®Google Scholar
• Wu D, Huang X, Jia C, et al. Clinical manifestation, distribution, and drug resistance of pathogens among abdominal solid organ transplant recipients with Klebsiella pneumoniae infections. Transplant Proc. 2020;52(1):289–294. doi:10.1016/j.transproceed.2019.11.023
   Web of Science ®Google Scholar
• Hasan MJ, Nizhu LN, Rabbani R. Bloodstream infection with pandrug-resistant Alcaligenes faecalis treated with double-dose of tigecycline. IDCases. 2019;18:e600. doi:10.1016/j.idcr.2019.e00600
   PubMed Web of Science ®Google Scholar
• Chinese Society Of Hematology, Chinese Medical Association, Chinese Hematology Association, Chinese Medical Doctor Association. Management of Carbapenem-resistant Enterobacteriaceae (CRE) infection in patients with hematological malignancies: Chinese consensus (2020). Zhonghua Xue Ye Xue Za Zhi. 2020;41(11):881–889. doi:10.3760/cma.j.issn.0253-2727.2020.11.001
   Google Scholar
• Freire MP, de Oliveira GD, Cury AP, et al. The role of therapy with aminoglycoside in the outcomes of kidney transplant recipients infected with polymyxin-and carbapenem-resistant Enterobacteriaceae. Eur J Clin Microbiol Infect Dis. 2019;38(4):755–765. doi:10.1007/s10096-019-03468-4
   PubMed Web of Science ®Google Scholar
• Zhang F, Zhong J, Ding H, et al. Efficacy of Ceftazidime-Avibactam in the treatment of Carbapenem-resistant Klebsiella pneumoniae infection after kidney transplantation. Infect Drug Resist. 2021;14:5165. doi:10.2147/IDR.S343505
   Web of Science ®Google Scholar
• Chen W, Sun L, Guo L, et al. Clinical outcomes of ceftazidime-avibactam in lung transplant recipients with infections caused by extensively drug-resistant gram-negative bacilli. Ann Transl Med. 2020;8(3):39. doi:10.21037/atm.2019.10.40
   PubMed Web of Science ®Google Scholar
• Chen F, Zhong H, Yang T, et al. Ceftazidime-avibactam as salvage treatment for infections due to Carbapenem-resistant Klebsiella pneumoniae in liver transplantation recipients. Infect Drug Resist. 2021;14:5603. doi:10.2147/IDR.S342163
   Web of Science ®Google Scholar
• Han J, Duan XG, Zhang SW, et al. In vitro anti-bacterial activity of ceftazidime/avibactam against carbapenem-resistant Klebsiella pneumoniae. Labeled Immunoassays Clin Med. 2021;28(11):1934–1937.
   Google Scholar
• Lee Y, Kim J, Trinh S. Meropenem-vaborbactam (Vabomere™): another option for carbapenem-resistant Enterobacteriaceae. P T. 2019;44(3):110.
   PubMedGoogle Scholar
• Wilson WR, Kline EG, Jones CE, et al. Effects of KPC variant and porin genotype on the in vitro activity of meropenem-vaborbactam against carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2019;63(3):e02048–18. doi:10.1128/AAC.02048-18
   PubMed Web of Science ®Google Scholar
• Maraki S, Mavromanolaki VE, Magkafouraki E, et al. Epidemiology and in vitro activity of ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, eravacycline, plazomicin, and comparators against Greek carbapenemase-producing Klebsiella pneumoniae isolates. Infection. 2022;50(2):467–474. doi:10.1007/s15010-021-01735-1
   PubMed Web of Science ®Google Scholar
• Agyeman AA, Bergen PJ, Rao GG, et al. A systematic review and meta-analysis of treatment outcomes following antibiotic therapy among patients with carbapenem-resistant Klebsiella pneumoniae infections. Int J Antimicrob Agents. 2020;55(1):105833. doi:10.1016/j.ijantimicag.2019.10.014
   PubMed Web of Science ®Google Scholar
• Tofas P, Skiada A, Angelopoulou M, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections in neutropenic patients with haematological malignancies or aplastic anaemia: analysis of 50 cases. Int J Antimicrob Agents. 2016;47(4):335–339. doi:10.1016/j.ijantimicag.2016.01.011
   PubMed Web of Science ®Google Scholar
• Luo X, Chen S, Zhang J, et al. Procalcitonin as a marker of Gram-negative bloodstream infections in hematological patients with febrile neutropenia. Leuk Lymphoma. 2019;60(10):2441–2448. doi:10.1080/10428194.2019.1581928
   PubMed Web of Science ®Google Scholar
• Schuetz P, Christ-Crain M, Muller B. Procalcitonin and other biomarkers to improve assessment and antibiotic stewardship in infections–hope for hype? Swiss Med Wkly. 2009;139(23–24):318–326.
   PubMed Web of Science ®Google Scholar
• Self WH, Wunderink RG, Jain S, et al. Procalcitonin as a marker of etiology in adults hospitalized with community-acquired pneumonia. Clin Infect Dis. 2018;66(10):1640–1641. doi:10.1093/cid/cix1090
   PubMed Web of Science ®Google Scholar
• Kim H, Roh YH, Yoon SH. Blood procalcitonin level as a diagnostic marker of pediatric bacterial meningitis: a systematic review and meta-analysis. Diagnostics. 2021;11(5):846. doi:10.3390/diagnostics11050846
   Web of Science ®Google Scholar
• Wang S, Chen D. The correlation between procalcitonin, C-reactive protein and severity scores in patients with sepsis and their value in assessment of prognosis. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2015;27(2):97–101. doi:10.3760/cma.j.issn.2095-4352.2015.02.004
   PubMedGoogle Scholar
• Gregoriano C, Heilmann E, Molitor A, et al. Role of procalcitonin use in the management of sepsis. J Thorac Dis. 2020;12(Suppl 1):S5–S15. doi:10.21037/jtd.2019.11.63
   PubMed Web of Science ®Google Scholar
• Styczynski J. Who is the patient at risk of CMV recurrence: a review of the current scientific evidence with a focus on hematopoietic cell transplantation. Infect Dis Ther. 2018;7(1):1–16. doi:10.1007/s40121-017-0180-z
   PubMed Web of Science ®Google Scholar
• Griffiths P. The direct and indirect consequences of cytomegalovirus infection and potential benefits of vaccination. Antiviral Res. 2020;176:104732. doi:10.1016/j.antiviral.2020.104732
   PubMed Web of Science ®Google Scholar
• Charlotte R, François P, Jonathan M, et al. Use of anti-CMV immunoglobulins in lung transplant recipients: the French experience. Transpl Infect Dis. 2021;23(6):e13754. doi:10.1111/tid.13754
   Web of Science ®Google Scholar
• Burns DM, Rana S, Martin E, et al. Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT. Bone Marrow Transplant. 2016;51(6):825–832. doi:10.1038/bmt.2016.19
   PubMed Web of Science ®Google Scholar
• Trecarichi EM, Pagano L, Martino B, et al. Bloodstream infections caused by Klebsiella pneumoniae in onc-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey. Am J Hematol. 2016;91(11):1076–1081. doi:10.1002/ajh.24489
   PubMed Web of Science ®Google Scholar
• Mario T, Maria TE, Giuseppe DRF, et al. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother. 2015;70(7):2133–2143. doi:10.1093/jac/dkv086
   Web of Science ®Google Scholar
• Petrosillo N, Taglietti F, Granata G. Treatment options for colistin resistant Klebsiella pneumoniae: present and future. J Clin Med. 2019;8(7):934. doi:10.3390/jcm8070934
   PubMed Web of Science ®Google Scholar